PedAM
Pediatric Disease Annotations & Medicines
| Disease | intestinal perforation |
| Phenotype | C0009402|colorectal cancer |
| Sentences | 2 |
| PubMedID- 25954110 | Methods: we compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts: (1) the agitg max trial (phase iii randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine, bevacizumab and mitomycinc); (2) the prospective treatment of recurrent and advanced colorectal cancer (tracc) registry (any first-line regimen +/- bevacizumab); and (3) two cancer centres in new south wales, australia [macarthur cancer therapy centre and liverpool cancer therapy centre (nswcc) from january 2005 to decenber 2012, (any first-line regimen +/- bevacizumab). |
| PubMedID- 25784840 | colorectal cancer with intestinal perforation - a retrospective analysis of treatment outcomes. |
Page: 1